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Abstract
We describe a 65-year-old Thai woman who developed cytomegalovirus retinitis (CMVR) in the setting of Good
syndrome—a rare, acquired partial immune deficiency caused by thymoma. The patient subsequently developed
vitritis with cystoid macular edema (CME) similar to immune recovery uveitis (IRU) despite control of the retinitis
with antiviral agents. A comprehensive review of the literature through December, 2014, identified an additional
279 eyes of 208 patients with CMVR in the absence of human immunodeficiency virus (HIV) infection. Including our
newly reported case, 9 of the 208 patients (4.3 %) had Good syndrome. Twenty-one of the 208 patients (10.1 %)
had CMVR related to intraocular or periocular corticosteroid administration. The remaining 178 patients (85.6 %)
acquired CMVR from other causes. Within the subset of patients who did not have Good syndrome or did not
acquire CMVR followed by intraocular or periocular corticosteroid administration, there were many other factors
contributing to a decline in immune function. The most common included age over 60 years (33.1 %), an underlying
malignancy (28.7 %), a systemic autoimmune disorder requiring systemic immunosuppression (19.1 %), organ (15.2 %)
or bone marrow (16.3 %) transplantation requiring systemic immunosuppression, and diabetes mellitus (6.1 %). Only
4.5 % of the patients had no identifiable contributor to a decline in immune function. While the clinical features of
CMVR are generally similar in HIV-negative and HIV-positive patients, the rates of moderate to severe intraocular
inflammation and of occlusive retinal vasculitis appear to be higher in HIV-negative patients.
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Introduction
Thymoma is an uncommon and slow-growing neoplasm
that accounts for approximately 20 to 30 % of medias-
tinal masses in adults and 1 % in children [1]. Thymic
tumors not only usually present with respiratory symp-
toms due to compression of the upper airways and/or
superior vena cava syndrome but also can produce para-
neoplastic or parathymic syndromes [1–4], and the most
common of which are myasthenia gravis (MG), pure red
cell aplasia (PRCA), and acquired partial immune defi-
ciency or Good syndrome [5, 6].
Good syndrome was first described by the American
hematologist-oncologist Dr. Robert Good in 1956 [7].
Good noted a direct relationship between the presence
of thymoma and hypogammaglobulinemia causing im-
munosuppression in those patients. Good syndrome typ-
ically occurs in middle-aged adults and is associated
most commonly with recurrent sinus and pulmonary in-
fections, cytomegalovirus (CMV) disease (most often
retinitis), fungal infections, pure red cell aplasia, and my-
asthenia gravis [8]. While hypogammaglobulinemia in
the setting of thymoma defines Good syndrome, other,
often partial, immune deficiencies have also been de-
scribed, including decreased T cell function [9].
We describe a 65-year-old woman who developed
CMV retinitis (CMVR) in the setting of Good syndrome.
The patient subsequently developed vitritis with cystoid
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macular edema (CME) despite control of the retinitis
with antiviral agents. Cases of CMVR in human im-
munodeficiency virus (HIV)-negative patients, including
those with Good syndrome, identified in PubMed
through December, 2014, were reviewed and are sum-
marized. Search terms included “Cytomegalovirus AND
eye” and “cytomegalovirus retinitis.” Additional publica-
tions were identified by reviewing collected references.
Case report
A 65-year-old Thai woman presented for evaluation of
suddenly decreased vision with floaters in her right eye.
Past ocular history was unremarkable. Past medical his-
tory was notable for PRCA diagnosed 2 years prior to
presentation and for which she was treated for four
months with erythropoietin and systemic corticosteroids.
She also had two prior episodes of oropharyngeal can-
didiasis, which were treated successfully. There was no
history of recent or current corticosteroid use.
The best-corrected vision was 20/100 on the right eye
and 20/25 on the left eye. Intraocular pressure (IOP)
was 15 mmHg bilaterally. No afferent pupillary defect
was noted. Anterior segment examination of the right
eye showed trace anterior chamber cell but was other-
wise normal. Anterior segment examination on the left
eye was unremarkable. Posterior segment examination
on the right showed moderate vitreous inflammation
and an advancing edge of necrotizing retinitis associated
with scattered intraretinal hemorrhages and retinal vas-
cular telangiectasis (Fig. 1a). Posterior segment examin-
ation of the left eye was unremarkable. The patient was
diagnosed clinically with viral retinitis, an anterior
chamber paracentesis was performed for viral DNA test-
ing, a laser barrier was applied immediately posterior to
the area of active retinitis, and the patient was given an
intravitreal injection of 2 mg of ganciclovir followed by
treatment with high-dose oral valaciclovir, 2 g three
times daily. Analysis of the anterior chamber paracen-
tesis was positive for CMV DNA, and the patient was
switched from valaciclovir to valganciclovir, which re-
sulted in resolution of the area of retinitis.
The patient subsequently underwent HIV and syphilis
testing, colonoscopy, chest X-ray, bone marrow biopsy,
and abdominal CT, all of which were negative. Testing
of immune function revealed a markedly decrease total
B cell (CD19) cell count and panhypogammaglobuline-
mia (Table 1).
Within 1 month of the diagnosis of CMVR, the patient
was hospitalized for acute pneumonia. During this
hospitalization, a mediastinal mass was discovered on
chest X-ray and evaluated further by chest CT (Fig. 2).
Computer tomography guided thymus biopsy and subse-
quent thymectomy were performed, revealing histo-
logical changes consistent with thymoma that lead to
the diagnosis of Good syndrome. Immunoglobulin A, G,
and M levels remained low at the last testing 5 months
following removal of the thymus. The patient then
returned with worsening vision in the eye with CMVR
while on maintenance valganciclovir therapy, 450 mg
twice daily.
The best-corrected vision was 20/125 on the right eye
and 20/25 on the left eye. Intraocular pressure was nor-
mal. No afferent pupillary defect was noted. Anterior
segment examination on the right showed several
Fig. 1 Color photograph of the patient’s right eye showing the active edge of cytomegalovirus retinitis (a), which became inactive following
treatment with an intravitreal injection of 2 mg of ganciclovir followed by high-dose oral valaciclovir, 2 g three times daily (b). Fluorescein angiography
(c) and SD-OCT imaging (d) showed the development of cystoid macular edema consistent with the diagnosis of immune recovery uveitis
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stellate keratic precipitates on the corneal endothelium,
one cell per high powered field in the anterior chamber,
and occasional anterior vitreous cells. Anterior segment
examination on the left was unremarkable. Posterior
segment examination on the right showed mild to mod-
erate vitreous inflammation, a posterior vitreous detach-
ment, a large area of inactive retinal necrosis (Fig. 1b),
continuous laser barrier scars immediately posterior to
the area of retinitis, and loss of the foveal light reflex
suggestive of CME. Posterior segment examination on
the left was unremarkable. Fluorescein angiography con-
firmed the presence of severe CME on the right (Fig. 1c).
Spectral domain optical coherence tomography (SD-
OCT) imaging showed marked CME on the right
(Fig. 1d) with a central macular thickness of 743 um.
SD-OCT imaging of the left fovea revealed a normal
contour with no evidence of subretinal or intraretinal
fluid. The patient was treated with topical difluprednate
four times daily for 1 month. The CME persisted, the
difluprednate was stopped, and the patient was given
two injections of 1.25 mg of intravitreal bevacizumab, 1
month apart. The CME failed to respond, and so the pa-
tient was given an intravitreal injection of triamcinolone
acetonide, 2.0 mg, following which the CME resolved
and vision improved to 20/80 in the affected eye. The
CME subsequently recurred and the vision decreased to
20/100, but the patient refused further treatment. The
retinitis remained inactive.
Comprehensive literature review
We describe a patient who developed CMVR in the set-
ting of Good syndrome, a rare occurrence reported in
eight previous patients to date (Tables 2 and 3) [10–16].
Including our patient, reported ages of the nine patients
ranged from 48 to 68 years, with both a mean and me-
dian of 56 years. Women constituted just over half of
the reported patients (55.5 %), with retinitis occurring
unilaterally in all but one patient (88.9 %) and involving
zone 1 in nearly two thirds of the affected eyes (62.5 %).
When reported, anterior chamber inflammation was
present in 62.5 % of cases; vitritis was present in 88.8 %
of cases and was reported to be moderate to severe in
five cases (55.5 %). The diagnosis was confirmed in all
but one patient (89.9 %) by polymerase chain reaction
(PCR)-based testing of intraocular fluids, and all cases
responded to antiviral therapy, which was administered
both intravitreally and systemically in six of nine
(66.6 %) patients. While the CMVR in our patient oc-
curred 1 month prior to the identification of thymoma,
a thymic tumor was identified prior to the development
of CMVR in the other eight patients, with a time ranging
from 1 month to just over 6 years prior to the occur-
rence of retinitis. Visual acuity at the initial CMVR diag-
nosis was between 20/40 and 20/200 in 77.8 and worse
than 20/200 in 22.2 % of eyes, whereas visual acuity at
last follow-up (median 6 months; range 1.5–7 months)
Table 1 Immunologic profile over time of currently reported case of cytomegalovirus retinitis in the setting of thymoma (Good’s
syndrome)
Immunologic profile At time of
retinitis
At time of CME diagnosis and
5 months after thymoma resection
6 months after CME and 11
months after thymoma resection
Reference range
T cells CD3 1079 (70 %) N/A 1284 (81 %) 672–2638 cells/mL (54–83 %)
T helper cells CD4 480 (31 %) N/A 437 (28 %) 292–1366 cells/mL (23.1–51.0 %)
Cytotoxic T cells CD 8 540 (35 %) N/A 817 (51 %) 240–1028 cells/mL (17.9–47.5 %)
CD4 to CD8 ratio 0.88 N/A 0.53 0.6–2.5
B cells CD19 40 (3 %) N/A 26 (2 %) 82–560 cells/mL (5.1–20.8 %)
Natural killer cells CD16/56 413 (27 %) N/A 277 (17 %) 130–938 cells/mL (7.1–38.0 %)
Immunoglobulin G 2.24 1.91 N/A 8–18 (g/L)
Immunoglobulin M <0.06 <0.06 N/A 0.5–2.2 (g/L)
Immunoglobulin A <0.04 0.6 N/A 1.1–5.6 (g/L)
Abbreviations: CME cystoid macular edema, CMV cytomegalovirus, NR not reported, IgG immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, CD
cluster designation, NK natural killer, N/A not available
Fig. 2 Chest CT showing a large mediastinal mass outlined in red
and found subsequently to be a thymoma
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Acuity worse than 20/
200: 2/9 eyes (22.2 %)
Range = 1.5–
7 months
Acuity worse than 20/






Abbreviations: IgG immunoglobulin G, M male, F female, U unilateral, BL bilateral, CMV cytomegalovirus, NR not reported, CF count fingers, NLP no light perception, LP light perception, HM hand motion, IV intravenous,
PO per oral, IVT intravitreal, PCR polymerase chain reaction
aAll patients were tested for HIV and found to be negative
bZone definitions are as follows: zone I defined as macula or optic nerve involvement; zone II defined as mid-periphery; and zone 3 defined as outer periphery. Zone definitions referenced in this paper: Cunningham
ET Jr, Hubbard LD, Danis RP, Holland GN. Proportionate topographic areas of retinal zones 1, 2, and 3 for use in describing infectious retinitis. Arch Ophthalmol. 2011;129(11):1507–8 [115]



















Table 3 Summary of autoimmune conditions and immunologic parameters in current and previously reported cases of cytomegalovirus (CMV) retinitis in the setting of





Other conditions encountered Lymphopeniaa Low CD3+ T cells (<672
cells/mL or <54 %)
Low CD4+ count
(<360/μL or <36 %)
Previously
published cases
Ho et al. (2010) [10] − − None + + +
Mateo-Montoya
et al. (2010) [11]
+ − None NR NR +
Park et al. (2009)
[12]
− − None + NR NR
Sen et al. (2005) [13] − − ?neurosensory hearing loss and optic neuropathy NR NR +
Wan et al. (2012)
[14]
NR + Autoimmune retinopathy (many years after diagnosis of
retinitis)
NR NR NR
Yong et al. (2008)
[15]
− − None + − +
Assi et al. (2002) [16]
case 1
+ − None − NR +
Assi et al. (2002) [16]
case 2
− − None NR NR NR
Current case Downes, et al.
(2013)
− + None − − −




No other definite autoimmune conditions encountered
at the time of diagnosis of retinitis
+3/5 reported
(60.0 %)



















Table 3 Summary of autoimmune conditions and immunologic parameters in current and previously reported cases of cytomegalovirus (CMV) retinitis in the setting of
immunodeficiency associated with thymoma (Good syndrome) (Continued)




Low NK cells (<130 cells/
mL or <7.1 %)
Hypogammaglobulinemia
IgG (IgG < 8 g/L)
Hypogammaglobulinemia
IgM (IgM <0.5 g/L)
Hypogammaglobulinemia
IgA (IgA < 1.1 g/L)
Panhypogammaglobulinemia (I
gG < 8 g/L, IgM <0.5 g/L, IgA < 1.1 g/
L, or total Ig < 9.6 g/L)
− + + + + + +
NR NR NR NR NR NR +
NR NR NR + + + +
NR + NR + + + +
NR NR NR NR NR NR NR
− + NR + + + +
NR + NR − − + −
− + NR + + + +
− − − + + + +
+0/4 reported (0.0 %) +5/6 reported
(83.3 %)
+1/2 reported (50.0 %) +7/8 reported hypo IgG
(87.5 %)
+7/8 reported hypo IgM
(87.5 %)




Abbreviations: CMV cytomegalovirus, NR not reported, IgG immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, CD cluster designation, NK natural killer



















was between 20/40 and 20/200 in 55.5 and worse than
20/200 in 44.4 % of eyes. Other common opportunistic
infections reported in these nine patients with Good
syndrome and CMVR included respiratory infections
(77.8 %), non-ocular CMV (22.2 %), and herpes zoster
dermatitis (33.3 %), whereas other autoimmune diseases
(Table 3) included MG (25.0 %) and PRCA (22.2 %).
Although the retinitis in our patient responded
promptly to intravitreal and systemic antiviral agents,
the patient subsequently developed vitritis and CME of
the type seen in patients with immune recovery uveitis
(IRU) despite the fact that her total CD4+ T cell count
was normal both before and after the occurrence of ret-
initis. In contrast, the total B cell count and immuno-
globulin levels where low both before and after
thymectomy. While hypogammaglobulinemia is required
to diagnose Good syndrome and has been observed in
all reported cases to date, including our patient, it is
noteworthy that the total CD4+ T cell count was some-
what decreased in five of the eight previously reported
cases with Good syndrome and CMVR (Table 3), indi-
cating that partial CD4+ T cell depletion does occur in
patients with Good syndrome and suggesting the possi-
bility that selective loss of CMV-targeting CD4+ T cells
may have occurred in our patient, facilitating the devel-
opment of retinitis. To our knowledge, an IRU-like syn-
drome has not been reported previously following
treatment of CMVR in a patient with Good syndrome.
Our review identified a total of 248 eyes of 178 pa-
tients previously reported with CMVR in the absence of
either HIV infection, Good syndrome, or prior periocular
or intraocular corticosteroid injection (Additional file 1:
Table S1) [17–86]. Reported ages ranged from 1 week to
84 years, with a mean and median of 45.7 and 48.0 years,
respectively. Men outnumbered women approximately
two to one (M to F ratio = 1.88:1), and the vast majority
(95.5 %) had an identifiable cause of systemic immunosup-
pression. The most common factors contributing to a de-
cline in immune function included age over 60 years
(33.1 %), an underlying malignancy (28.7 %), a systemic
autoimmune disorder requiring treatment (19.1 %), organ
(15.2 %) or bone marrow (16.3 %) transplantation requir-
ing systemic immunosuppression, and diabetes mellitus
(6.1 %). The most commonly reported cancers included
leukemia (35 patients; 19.7 %) and lymphoma (14 patients;
7.9 %). Three patients had multiple myeloma (1.7 %). One
patient each (0.6 %) had breast cancer and angiocentric
immunoblastic lymphadenopathy with dysproteinemia.
Several patients had a primary immune deficiency other
than Good syndrome, including three patients (1.7 %) with
severe combined immunodeficiency, two patients each
(1.1 %) with unspecified primary immune deficiency and
common variable immune deficiency, and one patient
(0.6 %) with idiopathic CD4+ T cell lymphopenia. Among
the 26 reported patients less 18 years of age, 9 (34.6 %)
had acute lymphoblastic leukemia, 8 (30.8 %) had under-
gone bone marrow transplantation, 5 (19.2 %) had con-
genital CMV infection, 3 (11.5 %) had severe combined
immunodeficiency and 1 each (3.8 %) had common vari-
able immune deficiency and immunoglobulin 2 (Ig2)
deficiency.
The use of systemic immunosuppressive medication
was reported in 105 of 160 cases (65.6 %). Seventy-eight
of these 105 patients (74.3 %) were on two or more im-
munosuppressive agents. Corticosteroids were the most
common immunosuppressive agent used in 69 patients
(65.7 %), followed by cyclophosphamide in 33 patients
(31.4 %), azathioprine in 17 patients (16.2 %), vincristine
in 16 patients (15.2 %), methotrexate in 15 patients
(14.3 %), cyclosporine in 13 patients (12.4 %), tacrolimus
in 11 patients (10.5 %), 6-mercaptopurine in 9 patients
(8.6 %), mycophenolate mofetil in 8 patients (7.6 %), flu-
darabine in 7 patients (6.7 %), and adriamycin in 6
patients (5.7 %). Five patients each (4.8 %) used intraven-
ous immunoglobulin G and rituximab. One patient each
(1.0 %) was on mitoxantrone, ibritumomab tiuxetan, and
hydroxychloroquine. Within the 105 cases reporting
medication use, the use of either an antimetabolite or a
leukocyte signaling inhibitor as a group (methotrexate,
azathioprine, mycophenolate mofetil, tacrolimus, or
cyclosporine) was reported in 46.7 % of cases, whereas
chemotherapeutic agents as a whole (cyclophosphamide,
vincristine, high-dose methotrexate, 6-mercaptopurine,
adriamycin, rituximab, fludarabine, mitoxantrone, and
ibritumomab tiuxetan) were reported in 48.6 % of cases.
Clinically, the retinitis was unilateral in 108 out of 178
cases (60.7 %). Many case reports provided limited clin-
ical information, but the location was either reported or
illustrated in 97 out of the 248 eyes (39.1 %) and was
found to involve zone 1 in 72 eyes (74.2 %). Additional
clinical features were noted in 200 out of 248 eyes
(80.6 %). Among these, 200 eyes, or just under one third
(29.0 %), were noted to have anterior chamber inflam-
mation, which was described as mild in 18 (9.0 %) and
moderate in 13 (6.5 %), and severe in the remaining 27
(13.5 %). Just over one third of the reported eyes
(37.5 %) were noted to have vitreous inflammation,
among which inflammation was described as mild in 23
(11.5 %), moderate in 18 (9.0 %), and severe in 6 (3.0 %),
with the remaining 28 (14.0 %) not quantifying severity.
An occlusive vasculitis was noted in 47 eyes (23.5 %).
Visual acuity at initial CMVR diagnosis was reported in
179 of 248 eyes (72.2 %). Among these 179 eyes, visual
acuity at initial diagnosis was better than 20/40 in
34.1 %, between 20/40 and 20/200 in 39.1 %, and worse
than 20/200 in 26.8 % of eyes. The method of diagnostic
confirmation of CMVR was reported in 131 of the 178
cases (73.6 %), among which the diagnosis of CMVR was
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confirmed by PCR-based testing of intraocular fluids in
71.8 %. The retinitis responded to antiviral therapy in all
cases. The treatment administered was reported in 126
of the 178 cases (70.8 %). Of these 126 cases, systemic
treatment was administered in 45.2 % of patients,
whereas both intravitreal and systemic therapy was given
in 31.0 % of patients, and intravitreal treatment alone
was employed in 23.8 % patients. Visual acuity at the last
follow-up visit was reported in 171 eyes (mean
14.2 months; median 6.0 months; range 0 to 216 months)
and was better than 20/40 in 30.4 %, between 20/40 and
20/200 in 37.4 %, and worse than 20/200 in 32.2 % of
eyes.
Recently, Takakura and colleagues reviewed the litera-
ture on patients who developed viral retinitis following
intraocular or periocular administration of corticoste-
roids [87]. Out of a total of 30 reported cases, 21
(70.0 %) developed CMVR (Table 4) [33, 87–100]. These
21 patients constituted 10.1 % of the total of 208 non-
HIV-positive patients with CMVR identified in our re-
view. Among the 21 patients with CMVR, reported ages
ranged from 30 to 84 years, with a mean and median of
66 and 69 years, respectively, and men outnumbered
women two to one (M to F ratio = 2:1). The most com-
mon underlying ocular diseases for which corticosteroids
were injected included diabetes mellitus (38.0 %), retinal
vein occlusion (33.3 %), and uveitic CME (33.3 %),
followed by choroidal neovascularization secondary to
age-related macular degeneration (9.5 %). In patients
with uveitis and CMVR, Behcet’s disease and anterior
uveitis comprised two cases each (28.5 %), followed by
one case each (14.3 %) of anterior uveitis, Vogt-Koyangi-
Harada disease, idiopathic posterior uveitis, and idio-
pathic panuveitis. The corticosteroid was administered
intravitreally in 19 of the 21 eyes (90.5 %). Among these
19 patients who received intravitreal corticosteroids, 8
(38.0 %) were administered between 1.5 and 4 mg, 4
(19.0 %) were administered between 8 and 20 mg, and 1
(4.8 %) was administered 40 mg of triamcinolone aceto-
nide. Two (9.0 %) were implanted with the fluocinolone
acetonide intravitreal implant (Retisert®). Among the two
patients who received periocular corticosteroids, one
(4.8 %) was administered 20 mg triamcinolone acetonide
while the other patient (4.8 %) was administered 40 mg.
The median time to developing retinitis after corticoster-
oid administration was 4.3 months with a mean of
4.0 months and a range 7 days to 13 months. Clinically,
the retinitis involved zone 1 in 20.0 % of the eyes and
was both unilateral and ipsilateral to the injection in all
cases. Twelve out of 21 cases (57.1 %) described some
clinical features of the retinitis. Within these 12 eyes, 10
(83.3 %) were noted to have anterior chamber inflamma-
tion, among which the inflammation was described as
mild in one case (8.3 %) and moderate in four cases
(33.3 %)—with the remaining seven (58.3 %) not quanti-
fying severity. Over ninety percent of the eyes (91.6 %)
were noted to have vitreous inflammation, among which
inflammation was described as moderate in four eyes
(33.3 %) with the remaining seven (63.6 %) not quantify-
ing the severity of the inflammation. An occlusive vascu-
litis was noted in seven eyes (58.3 %). Visual acuity at
initial CMVR diagnosis was reported in all 21 eyes and
was better than 20/40 in 2 eyes (9.5 %), between 20/40
and 20/200 in 11 eyes (52.3 %), and worse than 20/200
in 8 eyes (38.0 %). The diagnosis was confirmed by PCR-
based testing of intraocular fluids in 95.2 % of cases, and
all cases responded to antiviral therapy, which was ad-
ministered both intravitreally and systemically in 11 pa-
tients (52.3 %). Visual acuity at the last follow-up visit
(mean 11.8 months; median 5.5 months; range 1–84
months) was better than 20/40 in 2 eyes (9.5 %), be-
tween 20/40 and 20/200 in 8 eyes (38.0 %), and worse
than 20/200 in 11 eyes (52.3 %).
The most complete and standardized description of
CMVR in HIV-positive patients comes from the studies
performed by the Studies of the Ocular Complications
of AIDS (SOCA) research group [101–103]. Cyto-
megalovirus retinitis was the most frequently encoun-
tered complication of HIV infection in this cohort,
occurring in 34.6 % of patients with CD4+ T cell counts
<50 cells/μL and in 63.4 % of patients with CD4+ T cell
counts <200 cells/μL [104]. Clinically, HIV-associated
CMVR includes classic features of necrotizing retinitis
with irregular sheathing of adjacent vessels and variable
degrees of hemorrhage (sometimes referred to as “pizza
pie retinopathy” or “cottage cheese with ketchup”), and
which is sometimes coupled with a frost branch angiitis
appearance without vascular occlusion and often associ-
ated with mild vitreous or anterior chamber inflamma-
tion [12, 20, 104]. In addition to these core clinical
findings previously listed, the SOCA studies quantified
the prevalence of a number of hallmark features of
CMVR at presentation. Specifically, keratic precipitates
were present in 36.8 % of the eyes with CMVR, anterior
chamber inflammation in 46.2 %, and vitreous inflamma-
tion in 61.9 %. The prevalence of anterior chamber cells
greater than 2+ was 1.9 % and vitreous haze greater than
2+ was 11.4 %. Macular edema, epiretinal membrane
formation, and rhegmatogenous retinal detachment were
each uncommon at presentation in the SOCA cohort,
occurring in less than 10 % of the eyes, and posterior
synechiae formation was not observed [104].
A number of studies have suggested that the clinical
presentation of CMVR in HIV-negative patients can dif-
fer from that in HIV-positive patients [20–23, 27, 36,
94]. In a small series of eyes with CMVR in HIV-
negative patients complied by Maguire and associates in
1995, three eyes were found to have spontaneously
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Abbreviations: AMD age-related macular degeneration, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CME cystoid macular edema, CNVM choroidal neovascular membrane, DME diabetic
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natural killer, N/A not applicable
aZone definitions are as follows: zone I defined as macula or optic nerve involvement; zone II defined as mid-periphery; and zone 3 defined as outer periphery. Zone definitions referenced in this paper: Cunningham
ET Jr, Hubbard LD, Danis RP, Holland GN. Proportionate topographic areas of retinal zones 1, 2, and 3 for use in describing infectious retinitis. Arch Ophthalmol. 2011;129(11):1507-8 [115]



















regressed or indolent appearing CMVR associated with
vitritis and CME. The authors suggested that HIV-
negative CMVR was more often associated with moder-
ate to severe vitreous inflammation and CME [21]. The
tendency for HIV-negative CMVR to have more severe
intraocular inflammation as compared to CMVR in
HIV-positive patients has since been noted by a number
of authors, including Silverstein and colleagues [23],
Voros and associates [27], Tajunisah and colleagues [25],
Panthanapitoon and associates [22], and Schneider and
colleagues [36] with specific mention of a similarity to
acute retinal necrosis (ARN) in some eyes, including
both the severity of the inflammation and the presence
of occlusive vasculitis. In most instances, the more se-
vere inflammation and vascular occlusion was ascribed
to relative retention of anti-CMV immunoreactivity.
However, other studies have failed to identify consistent
difference in clinical presentation based on HIV status
[18–20, 24, 26, 30–33, 37–40, 44, 94, 95]. In our review,
of all the reported cases to date of HIV-negative CMVR
not associated with Good syndrome or following intra-
ocular or periocular administration of corticosteroids,
clinical features of the inflammation were reported in
199 of the 248 eyes (80.2 %). Within these 199 eyes, 13
(6.5 %) were specifically described as having moderate to
severe anterior chamber inflammation, 24 (12.1 %) as
having moderate to severe vitreous inflammation, and
47 (23.6 %) were noted to have occlusive vasculitis. In
HIV-negative CMVR associated with Good syndrome,
clinical features of the inflammation were reported in all
eyes. Within these 10 eyes, only 1 (10.0 %) was specific-
ally described as having moderate to severe anterior
chamber inflammation, whereas 5 out of 10 eyes
(50.0 %) were described as having moderate to severe
vitreous inflammation. None were noted to have occlu-
sive vasculitis. In HIV-negative CMVR following intraoc-
ular or periocular administration of corticosteroids,
clinical features of the inflammation were reported in 12
of the 21 eyes (57.1 %). Among these 12 eyes, 4 (33.3 %)
each were described as moderate to severe anterior
chamber inflammation or vitreous inflammation, and 6
(50.0 %) were noted to have occlusive retinal vasculitis.
Hence, while an ARN-like picture including moderate to
severe intraocular inflammation and the presence of oc-
clusive vasculitis may be somewhat more common in
HIV-negative as compared to HIV-positive CMVR, par-
ticularly in the setting of Good syndrome or following
periocular or intraocular corticosteroids, the clinical
presentation in these various cohorts appears, more
often than not, to be fairly similar, with an overlapping
clinical presentation (Table 5).
Immune recovery uveitis has been well characterized in
HIV-positive patients and is currently one of the most com-
mon causes of vision loss in patients with CMVR receiving
highly active antiretroviral therapy (HAART) [104, 105].
While the occurrence of IRU has varied widely in HIV-
positive cohorts receiving HAART, with reported rates ran-
ging from 3.0 to 63.3 % [106], the inflammation generally
occurs several weeks to months after initiating HAART, as
the number of circulating CD4+ T cells increases. The clin-
ical spectrum of IRU includes vitritis, papillitis, CME, epir-
etinal membrane formation, vitreous hemorrhage, retinal
neovascularization, vitreomacular traction syndrome, and
proliferative vitreoretinopathy [104–107].
Of the 248 eyes of 178 patients with CMVR in the ab-
sence of either HIV infection or Good syndrome that have
been described in the literature (Additional file 1: Table
S1), 16 eyes (6.5 %) of 10 patients had one or more fea-
tures consistent with IRU [17, 20, 45, 50, 70]. Reported
ages of these 10 patients ranged from 15 to 68 years, with
a mean and median of 47.8 and 54 years, respectively.
Men outnumbered women approximately two to one (M
to F ratio = 2.3:1), and the 100 % of the cases had an iden-
tifiable cause of systemic immunosuppression. The most
common factors contributing to a relative decline in im-
mune function included an underlying malignancy (n = 3;
30.0 %), age over 60 years (n = 2; 20.0 %), an autoimmune
disorder (n = 2; 20.0 %), organ (n = 3; 30.0 %) or bone mar-
row (n = 1; 10.0 %) transplantation requiring systemic im-
munosuppression, and diabetes mellitus (n = 1; 10.0 %).
The three reported cancers included two patients with
acute lymphoblastic leukemia and one patient with
chronic lymphocytic leukemia. The use of systemic im-
munosuppressive medication was reported in 8 out of the
10 cases (80.0 %). All of these patients were on two or
more immunosuppressive agents. Corticosteroids were
the most common immunosuppressive agent used in four
patients (50.0 %), followed by cyclophosphamide in three
patients (37.5 %), and two patients each (25.0 %) treated
with vincristine and mycophenolate mofetil. One patient
each (12.5 %) was treated with rituximab, fludarabine,
methotrexate, and tacrolimus. Clinically, the retinitis was
bilateral in 6 (60.0 %) out of 10 cases. Most case reports
provided limited clinical information, and the location was
either reported or illustrated in only 1 out of the 10 pa-
tients (10.0 %). In this patient, the retinitis was found to
involve zone II. Additional clinical features were noted in
5 out of 16 eyes (31.3 %). Among these five eyes, just two
eyes (40.0 %) were noted to have moderate anterior cham-
ber inflammation. All five eyes (100.0 %) were noted to
have vitreous inflammation, among which inflammation
was described moderate to severe in all cases. An occlu-
sive vasculitis was not present in any reported case of
CMVR associated with IRU. Visual acuity at initial CMVR
diagnosis was reported in 15 out of 16 eyes (93.8 %).
Among these 15 eyes, visual acuity at initial diagnosis was
better than 20/40 in 40.0 %, between 20/40 and 20/200 in
53.3 %, and worse than 20/200 in 6.7 % of eyes. The
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Table 5 Summary of cases of CMV retinitis in the literature without human immunodeficiency virus infection
CMV retinitis following intraocular
and periocular corticosteroid
injectiona
CMV retinitis in the setting of
immunodeficiency associated with
thymoma (Good syndrome)
CMV retinitis in immunocompetent
adults (non-Good syndrome)
Number of cases n = 21, n = 21 eyes n = 9, n = 10 eyes n = 178, n = 248 eyes
Age (years) Mean, 66.4 years Mean, 56 years Mean, 45.7 years
Median, 69 years Median, 56 years Median, 48.0 year
Range, 30.0–84.0 year Range, 48–68 years Range, 1 week–84 years
Gender Male, 14/21 (66.6 %) Male, 4/9 (44.4 %) Male, 113/173 reported (65.3 %)
Female, 7/21 (33.3 %) Female, 5/9 (55.5 %) Female, 60/173 reported (34.7 %)
Male to female ratio, 2:1 Male to female ratio, 0.8:1 Male to female ratio, 1.88:1
% unilateral 21/21 (100 %) 8/9 (88.9 %) 108/178 (60.7 %) unilateral
Indication for corticosteroid RVO, 7/21 (33.3 %) N/A N/A
DME, 8/21 (38.0 %)
Uveitic CME, 7/21 (33.3 %)
CNVM due to AMD, 2/21 (9.5 %)
IRU, 0/21 (0.0 %)
Corticosteroid dose/route 1.5–4 mg IVT, 8/21 (38.0 %) N/A N/A
8–20 mg, 5/21 (23.8 %)
40 mg, 2/21 (9.0 %)
FA implant, 2/21 (9.0 %)
Range, 1.5–40 mg
Time from corticosteroid
dosing to retinitis (months)
Mean, 4.3 months N/A N/A
Median, 4.0 months
Range, 0.25–13.0 months
Timing of CMV retinitis
relative to thymoma diagnosis
(months)b
N/A Retinitis diagnosed after thymoma, 8/9
(88.9 %)
N/A
Mean, 31.4 months after thymoma
Median, 24 months after thymoma
Range, 75 months after to 1 month before
Associated systemic diseasesb N/A Respiratory infections, 7/9 (77.7 %) No underlying systemic illness,9/
178 (5.1 %)
Non-ocular CMV, 2/9 (22.2 %) Organ or bone marrow transplant,
61/178 (34.3 %)
Other opportunistic infections, 3/9 (33.3 %) Autoimmune disease, 34/178
(19.1 %)
Leukemia or lymphoma, 51/178
(28.7 %)
Primary immune deficiency, 10/178
(5.6 %)









medication, 78/105 (74.3 %)
Using chemotherapy, 51/105
(48.6 %)
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Table 5 Summary of cases of CMV retinitis in the literature without human immunodeficiency virus infection (Continued)





N/A Myasthenia gravis, 2/8 reported (25.0 %) N/A
Pure red cell aplasia, 2/9 cases (22.2 %)
Associated immunologic
laboratory abnormalities
N/A Generalized lymphopenia: 3/5 reported
(60.0 %)
N/A
Low CD3+ T cells (<672 /mL), 1/3 reported
(33.3 %)
Low CD4+ T cells (<360/μL), 5/6 reported
(83.3 %)
Low CD 8 count (<240 /μL), 0/4 reported
(0.0 %)
Low CD4+/CD8+ ratio (<0.6), 5/6 reported
(83.3 %)
Low NK cells (<130 /mL), 1/2 reported
(50.0 %)
Low serum IgG (<8 g/L), 7/8 reported
(87.5 %)
Low serum IgM (<0.5 g/L), 7/8 reported
(87.5 %)




CMV testing Positive aqueous or vitreous PCR,
20/21 (95.2 %)
Positive aqueous PCR, 4/9 (44.4 %) Positive aqueous PCR, 65/131
reported (49.6 %)
Confirmed by other means, 1/21
(4.8 %)
Positive vitreous PCR, 5/9 (55.5 %) Positive vitreous PCR, 29/131
reported (22.1 %)
Confirmed by other means, 1/9 (11.1 %) Confirmed by other means, 37/131
reported (28.2 %)
Zone involvedc Zone I, 4/20 reported (20.0 %) Zone I, 5/8 reported (62.5 %) Zone I, 72/97 eyes reported
(74.2 %)
Zone II, 17/20 reported (85.0 %) Zone II, 4/8 reported (50 %) Zone II, 87/97 eyes reported
(89.7 %)
Zone III, 1/20 reported (5.0 %) Zone III, 2/8 reported (25 %) Zone III, 39/97 eyes reported
(40.2 %)
Vision when retinitis was first
diagnosed
Acuity better than 20/40, 2/21
eyes (9.5 %)
Acuity better than 20/40, 0/9 eyes (0.0 %) Acuity better than 20/40, 61/179
reported eyes (34.1 %)
Acuity between 20/40 and 20/200,
11/21 eyes (52.3 %)
Acuity between 20/40 and 20/200, 7/9 eyes
(77.7 %)
Acuity between 20/40 and 20/200,
70/179 reported eyes (39.1 %)
Acuity worse than 20/200, 8/21
eyes (38.0 %)
Acuity worse than 20/200, 2/9 eyes (22.2 %) Acuity worse than 20/200, 48/179
reported eyes (26.8 %)
Retinitis treatmentd Intravitreal therapy alone, 5/21
(23.8 %)
Intravitreal therapy alone, 1/9 (11.1 %) Intravitreal therapy alone, 30/126
reported (23.8 %)
Systemic therapy alone, 5/21
(23.8 %)
Systemic therapy alone, 2/9 (22.2 %) Systemic therapy alone, 57/126
reported (45.2 %)
Intravitreal and systemic therapy,
12/21 (52.3 %)
Intravitreal and systemic therapy, 6/9
(66.6 %)
Intravitreal and systemic therapy,
39/126 reported (31.0 %)
Follow-up (months) Mean = 11.8 months Mean = 4.56 months Mean = 14.2 months
Median = 5.5 months Median = 6 months Median = 6.0 months
Range = 1–84 months Range = 1.5–7 months Range = 0–216 months
Vision at the last visit Acuity better than 20/40, 2/21
eyes (9.5 %)
Acuity better than 20/40, 0/9 eyes (0.0 %) Acuity better than 20/40, 52/171
reported eyes (30.4 %)
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method of diagnostic confirmation of CMVR was reported
in 1 of the 10 cases (10.0 %), among which the diagnosis
of CMVR was confirmed serum PCR testing. The retinitis
responded to antiviral therapy in all cases. The therapeutic
treatment administered was reported in 6 of the 10 cases
(60.0 %). Of these 6 cases, treatment was administered
systemically only in 33.3 % of patients and intravitreally
alone in 66.7 % patients. Visual acuity at last follow-up
visit was reported in 8 patients and 13 eyes (mean
22.2 months; median 19 months; range 1 to 43 months).
Visual acuity at last follow-up was better than 20/40 in
38.5 %, between 20/40 and 20/200 in 46.1 %, and worse
than 20/200 in 15.4 % of eyes.
Since the December, 2014, cutoff for our literature re-
view, there have been several publications of CMVR in
HIV-negative patients [108–113]. While these publica-
tions are not incorporated into this review, the clinical
context in which CMVR developed and the clinical char-
acteristics of the retinitis and the treatment(s) given for
the infection were not significantly different from those
previously reported or from the conclusions drawn by
our review [114].
Conclusions
Although uncommon, CMVR can occur in the absence
of HIV infection. Over 95 %, of HIV-negative patients
who developed CMVR were found, ultimately, to have
one or more factors contributing to a relative decline in
immune function, such as advanced age, an underlying
malignancy, an autoimmune disease or organ/bone
transplantation requiring systemic immunosuppression,
administration of periocular or intraocular corticoste-
roids, diabetes mellitus, or, less commonly, an inherited
or acquired immune disorder, such as Good syndrome.
While the clinical features of CMVR were generally
similar in HIV-negative and HIV-positive patients, accu-
mulated data regarding the rate of moderate to severe
intraocular inflammation and occlusive retinal vasculitis
would seem to suggest that these more ARN-like fea-
tures occur more often in HIV-negative patients.
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Additional file 1: Table S1. Summary of reported cases of
cytomegalovirus (CMV) retinitis in immunocompetent HIV-negative
patients. (DOC 497 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KD is the primary author who was responsible for conceiving the study, the
acquisition of the data, and the analysis and interpretation. He drafted the
manuscript and revised it critically for content. DT and LW were also
responsible for the acquisition of the data and reading and approving the
final manuscript. ETC was responsible for conceiving the study, participated
in the review design, and revised the manuscript critically for content. ETC
read and approved the final manuscript. All authors read and approved the
final manuscript.
Authors’ information
Kenneth M. Downes, M.D. is a resident physician at California Pacific Medical
Center. Dariusz Tarasewicz, M.D., Ph.D. is a physician at the Department of
Ophthalmology at Kaiser Permanente Medical Center in South San Francisco,
California. Laurie J. Weisberg, MD is a physician at the Department of
Hematology/Oncology at Kaiser Permanente South San Francisco Medical
Center in South San Francisco, California. Emmett T. Cunningham Jr., M.D.,
M.P.H., Ph.D. is a physician at the West Coast Retina Medical Group in San
Francisco, California.
Acknowledgements
This study is supported in part by The Pacific Vision Foundation and The San
Francisco Retina Foundation (ETC.).
Author details
1The Department of Ophthalmology, California Pacific Medical Center, 2340
Clay Street 5th, San Francisco, CA 94115, USA. 2The Department of
Ophthalmology, Kaiser Permanente Medical Center, South San Francisco, CA,
USA. 3The Department of Hematology/Oncology, Kaiser Permanente South
San Francisco Medical Center, South San Francisco, CA, USA. 4The
Department of Ophthalmology, Stanford University School of Medicine,
Stanford, CA, USA. 5The Francis I. Proctor Foundation, UCSF School of
Medicine, San Francisco, CA, USA. 6West Coast Retina Medical Group, San
Francisco, CA, USA.
Received: 24 September 2015 Accepted: 4 January 2016
References
1. Liang X, Lovell MA, Capocelli KE et al (2010) Thymoma in children: report of
2 cases and review of the literature. Pediatr Dev Pathol 13(3):202–208
Table 5 Summary of cases of CMV retinitis in the literature without human immunodeficiency virus infection (Continued)
Acuity between 20/40 and 20/200,
8/21 eyes (38.0 %)
Acuity between 20/40 and 20/200, 5/9 eyes
(55.5 %)
Acuity between 20/40 and 20/
200,:64/171 reported eyes (37.4 %)
Acuity worse than 20/200, 11/21
eyes (52.3 %)
Acuity worse than 20/200, 4/9 eyes (44.4 %) Acuity worse than 20/200, 55/171
reported eyes (32.2 %)
Abbreviations: AMD age-related macular degeneration, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CME cystoid macular
edema, CNVM choroidal neovascular membrane, DME diabetic macular edema, ERM epiretinal membrane, FA fluocinolone acetonide, IRU immune recovery
uveitis, IgG immunoglobulin G, CMV cytomegalovirus, NR not reported, PCR polymerase chain reaction, CD cluster designation, NK natural killer, N/A
not applicable
aData used from paper done by Takakura et al. [89] currently in peer review “Ocular Immunology and Inflammation”
bAll patients were HIV negative
cZone definitions are as follows: Zone I defined as macula or optic nerve involvement; Zone II defined as mid-periphery; Zone 3 defined as outer periphery. Zone
definitions referenced in this paper: Cunningham ET Jr, Hubbard LD, Danis RP, Holland GN. Proportionate topographic areas of retinal zones 1, 2, and 3 for use in
describing infectious retinitis. Arch Ophthalmol. 2011;129(11):1507–8 [115]
dDosing with each modality varied widely across studies
Downes et al. Journal of Ophthalmic Inflammation and Infection  (2016) 6:3 Page 16 of 19
2. Cucchiara BL, Forman MS, McGarvey ML et al (2003) Fatal Subacute
Cytomegalovirus Encephalitis Associated with Hypogammaglobulinemia
and Thymoma. Mayo Clin Proc 78(2):223–227
3. Kelleher P, Misbah SA (2003) Review: What is Good's syndrome? Immunological
abnormalities in patients with thymoma. J Clin Pathol 56(1):12–16
4. Kitamura A, Takiguchi Y, Tochigi N et al (2009) Durable
Hypogammaglobulinemia Associated with Thymoma (Good syndrome).
Inter Med 48(19):1749–1752
5. Leibovitz I, Zamir D, Polychuck I et al (2003) Brief report. Recurrent
Pneumonia Post-Thymectomy as a Manifestation of Good Syndrome. Eur J
of Intern Med 14(1):60–62
6. Robinson MR et al (2000) Immune-Recovery Uveitis in Patients With
Cytomegalovirus Retinitis Taking Highly Active Antiretroviral Therapy. Am J
Ophthalmol 130(1):49–56
7. Good RA et al (1956) Thymic Tumor and Acquired Agammaglobulinemia: A
Clinical and Experimental Study of the Immune Response. Surgery 40(6):
1010–7
8. Kelesidis T et al (2010) Good's Syndrome Remains a Mystery After 55 years:
A Systematic Review of the Scientific Evidence. Clinical Immunology 135:
347–363
9. Miao H, Tao Y, Jiang YR, Li XX (2013) Multiple intravitreal injections of
ganciclovir for cytomegalovirus retinitis after stem-cell transplantation.
Graefes Arch Clin Exp Ophthalmol 251(7):1829–33. doi:10.1007/s00417-013-
2368-6
10. Ho JK et al (2010) A rare combination of recurrent pneumonia, diarrhoea,
and visual loss in a patient after thymectomy: Good syndrome. Hong Kong
Med J 16(6):493–6
11. Mateo-Montoya A et al (2010) Cytomegalovirus retinitis associated with
Good’s Syndrome. Eur J Ophthalmol 20(2):479–480
12. Park D et al (2010) Bilateral Cytomegalovirus Retinitis with Unilateral Optic
Neuritis in Good Syndrome. Jpn J Ophthalmol 54(3):246–8
13. Sen H et al (2005) CMV Retinitis in a Patient with Good Syndrome. Ocul
Immunol Inflamm 13:475–478
14. Wan C et al (2013) Autoimmune Retinopathy in Benign Thymoma after
Good Syndrome-associated Cytomegalovirus Retinitis. Ocul Immunol
Inflamm 21(1):64–66
15. Yong D et al (2008) Good’s syndrome in a patient with cytomegalovirus
retinitis. Hong Kong Med J 14:142–4
16. Assi A et al (2002) Cytomeagalovirus retinitis in Patients with Good
Syndrome. Arch Ophthalmol 120(4):510–2
17. Bessho K, Schrier RD, Freeman WR (2007) Immune Recovery Uveitis in a
CMV Retinitis Patient Without HIV Infection. Retin Cases Brief Rep I:52–53
18. Chawla HB, Ford MJ, Munro JF, Scorgie RE, Watson AR (1976) Ocular
involvement in cytomegalovirus infection in a previously healthy adult. Br
Med J 2(6030):281–2
19. England AC 3rd, Miller SA, Maki DG (1982) Ocular Findings of Acute
Cytomegalovirus Infection in an Immunologically Competent Adult. N Engl
J Med 307:94–95
20. Kuo IC, Kempen JH, Dunn JP, Vogelsang G, Jabs DA (2004) Clinical
characteristics and outcomes of cytomegalovirus retinitis in persons without
human immunodeficiency virus infection. Am J Ophthalmol 138(3):338–46
21. Maguire AM, Nichols CW, Crooks GW (1996) Visual loss in cytomegalovirus
retinitis caused by cystoid macular edema in patients without the acquired
immune deficiency syndrome. Ophthalmology 103(4):601–5
22. Pathanapitoon K, Tesavibul N, Choopong P, Boonsopon S, Kongyai N,
Ausayakhun S, Kunavisarut P, Rothova A (2013) Clinical manifestations of
cytomegalovirus-associated posterior uveitis and panuveitis in patients without
human immunodeficiency virus infection. JAMA Ophthalmol 131(5):638–45
23. Silverstein BE, Conrad D, Margolis TP, Wong IG (1997) Cytomegalovirus-
associated acute retinal necrosis syndrome. Am J Ophthalmol 123(2):257–8
24. Stewart MW, Bolling JP, Mendez JC (2005) Cytomegalovirus retinitis in an
immunocompetent patient. Arch Ophthalmol 123(4):572–4
25. Tajunisah I, Reddy SC, Tan LH (2009) Acute retinal necrosis by
cytomegalovirus in an immunocompetent adult: case report and review of
the literature. Int Ophthalmol 29(2):85–90
26. López-Contreras J, Ris J, Domingo P, Puig M, Rabella N, Nolla J (1995)
Disseminated cytomegalovirus infection in an immunocompetent adult
successfully treated with ganciclovir. Scand J Infect Dis 27(5):523–5
27. Voros GM, Pandit R, Snow M, Griffiths PG (2006) Unilateral recurrent acute
retinal necrosis syndrome caused by cytomegalovirus in an immune-
competent adult. Eur J Ophthalmol 16(3):484–6
28. Tran TH, Rozenberg F, Cassoux N, Rao NA, LeHoang P, Bodaghi B (2003)
Polymerase chain reaction analysis of aqueous humour samples in
necrotising retinitis. Br J Ophthalmol 87(1):79–83
29. Radwan A, Metzinger JL, Hinkle DM, Foster CS (2013) Cytomegalovirus
retinitis in immunocompetent patients: case reports and literature review.
Ocul Immunol Inflamm 21(4):324–8
30. Aghamohammadi A, Abolhassani H, Hirbod-Mobarakeh A, Ghassemi F,
Shahinpour S, Behniafard N, Naghibzadeh G, Imanzadeh A, Rezaei N (2012)
The uncommon combination of common variable immunodeficiency,
macrophage activation syndrome, and cytomegalovirus retinitis. Viral
Immunol 25(2):161–5
31. Coors LE, Spencer R (2010) Delayed presentation of cytomegalovirus retinitis
in an infant with severe congenital cytomegalovirus infection. Retina 30(4
Suppl):S59–62
32. Gupta S, Vemulakonda GA, Suhler EB, Yeh S, Albini TA, Mandelcorn E, Flaxel
CJ (2013) Cytomegalovirus retinitis in the absence of AIDS. Can J
Ophthalmol 48(2):126–9
33. Moritake H, Kamimura S, Kojima H, Shimonodan H, Harada M, Sugimoto T,
Nao-I N, Nunoi H (2013) Cytomegalovirus retinitis as an adverse
immunological effect of pulses of vincristine and dexamethasone in
maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr
Blood Cancer 60(2):329–31
34. Mota A, Breda J, Silva R, Magalhães A, Falcão-Reis F (2011) Cytomegalovirus
retinitis in an immunocompromised infant: a case report and review of the
literature. Case Rep Ophthalmol 2(2):238–42
35. Samia L, Hamam R, Dbaibo G, Saab R, El-Solh H, Abboud M (2013) Muwakkit
S. Cytomegalovirus retinitis in children and young adults with acute
lymphoblastic leukemia in Lebanon, Leuk Lymphoma
36. Schneider EW, Elner SG, van Kuijk FJ, Goldberg N, Lieberman RM, Eliott D,
Johnson MWCHRONICRETINALNECROSIS (2013) Cytomegalovirus
Necrotizing Retinitis Associated With Panretinal Vasculopathy in Non-HIV
Patients. Retina 33(9):1791–9
37. Singh R, Singh R, Trehan A, Jain R, Bhalekar S (2013) Cytomegalovirus
Retinitis in an ALL child on exclusive chemotherapy treated successfully
with intravitreal ganciclovir alone. J Pediatr Hematol Oncol 35(3):e118–9
38. Squires JE, Sisk RA, Balistreri WF, Kohli R (2013) Isolated unilateral
cytomegalovirus retinitis: a rare long-term complication after pediatric liver
transplantation. Pediatr Transplant 17(1):E16–9
39. Svozílková P, Heissigerová J, Brichová M, Kalvodová B, Dvořák J, Ríhová E
(2013) A possible coincidence of cytomegalovirus retinitis and intraocular
lymphoma in a patient with systemic non-Hodgkin's lymphoma. Virol J 10:18
40. Wakai K, Sano H, Shimada A, Shiozawa Y, Park MJ, Sotomatsu M,
Yanagisawa R, Koike K, Kozawa K, Ryo A, Tsukagoshi H, Kimura H, Hayashi Y
(2013) Cytomegalovirus retinitis during maintenance therapy for T-cell acute
lymphoblastic leukemia. J Pediatr Hematol Oncol 35(2):162–3
41. Squirrell DM (2013) Bhatta S. Mudhar HS, Rennie IG. Hypertensive
iridocyclitis associated with delayed onset biopsy proven Cytomegalovirus
retinitis. Indian J Ophthalmol
42. Takayama K, Ogawa M, Mochizuki M, Takeuchi M (2013) Cytomegalovirus
retinitis in a patient with proliferative diabetes retinopathy. Ocul Immunol
Inflamm 21(3):225–6
43. Yashiro S, Fujino Y, Tachikawa N, Inamochi K, Oka S (2013) Long-term
control of CMV retinitis in a patient with idiopathic CD4+ T
lymphocytopenia. J Infect Chemother 19(2):316–20
44. Moss HB, Chavala S, Say E, Miller MB (2012) Ganciclovir-resistant
cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her
plasma. J Clin Microbiol 50(5):1796–9
45. Agarwal A, et al. Outcome of cytomegalovirus retinitis in
immunocompromised patients without Human Immunodeficiency Virus
treated with intravitreal ganciclovir injection. Graefes Arch Clin Exp
Ophthalmol. Feb 21, 2014
46. Bertelmann E, Liekfeld A, Pleyer U, Hartmann C (2005) Cytomegalovirus
retinitis in Wegener's granulomatosis: case report and review of the
literature. Acta Ophthalmol Scand 83(2):258–61, Review
47. Chou PI, Lee H, Lee FY (1996) Cytomegalovirus retinitis after heart
transplant: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 57(4):310–3
48. Church J, Goyal S, Tyagi AK, Scott RA, Stavrou P (2007) Cytomegalovirus retinitis
in chronic lymphocytic leukaemia. Eye (Lond) 21(9):1230–3, 2006 Aug 18
49. Egli A, Bergamin O, Müllhaupt B, Seebach JD, Mueller NJ, Hirsch HH (2008)
Cytomegalovirus-associated chorioretinitis after liver transplantation: case
report and review of the literature. Transpl Infect Dis 10(1):27–43, 2007 Dec 17
Downes et al. Journal of Ophthalmic Inflammation and Infection  (2016) 6:3 Page 17 of 19
50. Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR (2008) Clinical features and
outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect
Dis 10(1):13–8, 2007 May 19
51. Gooi P, Farmer J, Hurley B, Brodbaker E (2008) Cytomegalovirus retinitis
mimicking intraocular lymphoma. Clin Ophthalmol 2(4):969–71
52. Haerter G, Manfras BJ, de Jong-Hesse Y, Wilts H, Mertens T, Kern P, Schmitt
M (2004) Cytomegalovirus retinitis in a patient treated with anti-tumor
necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect
Dis 39(9):e88–94, 2004 Oct 11
53. Hoang QV, Simon DM, Kumar GN, Oh F, Goldstein DA (2010) Recurrent CMV
retinitis in a non-HIV patient with drug-resistant CMV. Graefes Arch Clin Exp
Ophthalmol 248(5):737–40. doi:10.1007/s00417-009-1283-3, 2010 Jan 22
54. Ishikawa K, Ando Y, Narita M, Shinjoh M, Iwasaki T (2002) Cytomegalovirus
retinitis during immunotherapy for common variable immunodeficiency. J
Infect 44(1):55–6
55. Kaulfersch W, Urban C, Hauer C, Lackner H, Gamillscheg A, Slavc I, Langmann G
(1989) Successful treatment of CMV retinitis with ganciclovir after allogeneic
marrow transplantation. Bone Marrow Transplant 4(5):587–9
56. Kim HR, Kim SD, Kim SH, Yoon CH, Lee SH, Park SH, Kim HY (2007)
Cytomegalovirus retinitis in a patient with dermatomyositis. Clin Rheumatol
26(5):801–3, 2006 Mar 15
57. Kobayashi R, Takanashi K, Suzuki D, Nasu T, Uetake K, Matsumoto Y (2012)
Retinitis from cytomegalovirus during maintenance treatment for acute
lymphoblastic leukemia. Pediatr Int 54(2):288–90
58. Lafaut BA, Vianna RN, De Baets F, Meire F (1995) Unilateral cytomegalovirus
retinitis in a patient with immunoglobulin G2 deficiency. Ophthalmologica
209(1):40–3
59. Larsson K, Lönnqvist B, Ringdén O, Hedquist B, Ljungman P (2002) CMV
retinitis after allogeneic bone marrow transplantation: a report of five cases.
Transpl Infect Dis 4(2):75–9
60. Lee JJ, Teoh SC, Chua JL, Tien MC, Lim TH (2006) Occurrence and
reactivation of cytomegalovirus retinitis in systemic lupus erythematosus
with normal CD4(+) counts. Eye (Lond) 20(5):618–21
61. Long HM, Dick A (2005) Presumed CMV associated necrotizing retinopathy
in a non-HIV immunocompromised host. Clin Experiment Ophthalmol 33(3):
330–2
62. Margo CE, Arango JL (1998) Cytomegalovirus retinitis and the lupus
anticoagulant syndrome. Retina 18(6):568–70
63. Nasir MA, Jaffe GJ (1996) Cytomegalovirus retinitis associated with
Hodgkin's disease. Retina 16(4):324–7
64. Raz J, Aker M, Engelhard D, Ramu N, Or R, Cohen E, Nagler A, Benezra D
(1993) Cytomegalovirus retinitis in children following bone marrow
transplantation. Ocul Immunol Inflamm 1(3):263–8
65. Scott WJ, Giangiacomo J, Hodges KE (1986) Accelerated cytomegalovirus
retinitis secondary to immunosuppressive therapy. Arch Ophthalmol 104(8):
1117–8, 1124
66. Shimakawa M, Kono C, Nagai T, Hori S, Tanabe K, Toma H (2002) CMV
retinitis after renal transplantation. Transplant Proc 34(5):1790–2
67. Song WK, Min YH, Kim YR, Lee SC (2008) Cytomegalovirus retinitis after
hematopoietic stem cell transplantation with alemtuzumab. Ophthalmology
115(10):1766–70
68. Tranos PG, Georgalas I, Founti P, Ladas I (2008) Cytomegalovirus retinitis
presenting as vasculitis in a patient with Wegener's granulomatosis. Clin
Ophthalmol 2(4):961–3
69. Vote B, Russell M, Polkinghorne P (2005) Recurrent cytomegalovirus retinitis
in a patient with a normal lymphocyte count who had undergone
splenectomy for lymphoma. Retina 25(2):220–1
70. Wimmersberger Y, Balaskas K, Gander M, Pournaras JA, Guex-Crosier Y
(2011) Immune recovery uveitis occurring after chemotherapy and ocular
CMV infection in chronic lymphatic leukaemia. Klin Monbl Augenheilkd
228(4):358–9
71. Winkler A, Finan MJ, Pressly T, Roberts R (1987) Cytomegalovirus retinitis in
rheumatic disease: a case report. Arthritis Rheum 30(1):106–8
72. Davis JL, Haft P, Hartley K (2013) Retinal arteriolar occlusions due to
cytomegalovirus retinitis in elderly patients without HIV. J Ophthalmic
Inflamm Infect 3(1):17. doi:10.1186/1869-5760-3-17
73. Goldhardt R, Gregori NZ, Albini T, Yalamanchi S, Emanuelli A (2012)
Posterior subhyaloid precipitates in cytomegalovirus retinitis. J Ophthalmic
Inflamm Infect 2(1):41–5. doi:10.1007/s12348-011-0032-z, 2011 Jul 29
74. Iwanaga M, Zaitsu M, Ishii E, Nishimura Y, Inada S, Yoshiki H, Okinami S,
Hamasaki Y (2004) Protein-losing gastroenteropathy and retinitis associated
with cytomegalovirus infection in an immunocompetent infant: a case
report. Eur J Pediatr 163(2):81–4, 2003 Dec 5
75. Kabata Y, Takahashi G, Tsuneoka H (2012) Cytomegalovirus retinitis treated
with valganciclovir in Wegener's granulomatosis. Clin Ophthalmol 6:521–3.
doi:10.2147/OPTH.S31130, 2012 Mar 27
76. Kelkar A, Kelkar J, Kelkar S, Bhirud S, Biswas J (2011) Cytomegalovirus retinitis
in a seronegative patient with systemic lupus erythematosus on
immunosuppressive therapy. J Ophthalmic Inflamm Infect 1(3):129–32.
doi:10.1007/s12348-010-0017-3, 2011 Apr 3
77. Libby E, Movva S, Quintana D, Abdul-Jaleel M, Das A (2010)
Cytomegalovirus retinitis during chemotherapy with rituximab plus
hyperfractionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone. J Clin Oncol 28(32):e661–2. doi:10.1200/JCO.2010.29.6467,
2010 Sep 20
78. Oschman A, Murthy V, Kollipara R, Kenneth Lord R, Oluola O (2013)
Intravitreal ganciclovir for neonatal cytomegalovirus-associated retinitis: a
case report. J Perinatol 33(4):329–31. doi:10.1038/jp.2012.139
79. Patel MP, Kute VB, Gumber MR, Shah PR, Patel HV, Dhananjay KL, Jain SH,
Trivedi HL, Vanikar AV (2013) Successful treatment of Nocardia pneumonia
with cytomegalovirus retinitis coinfection in a renal transplant recipient. Int
Urol Nephrol 45(2):581–5
80. Piersigilli F, Catena G, De Gasperis MR, Lozzi S, Auriti C (2012) Active retinitis
in an infant with postnatally acquired cytomegalovirus infection. J Perinatol
32(7):559–62. doi:10.1038/jp.2011.142
81. Teh BW, Khot AS, Harrison SJ, Prince HM, Slavin MA (2013) A messenger at
the door: cytomegalovirus retinitis in myeloma patients with progressive
disease. Transpl Infect Dis 15(4):E134–8. doi:10.1111/tid.12106, 2013 Jun 23
82. Toriyama K, Suzuki T, Hara Y, Ohashi Y (2012) Cytomegalovirus retinitis after
multiple ocular surgeries in an immunocompetent patient. Case Rep
Ophthalmol 3(3):356–9. doi:10.1159/000343705, 2012 Oct 23
83. Tuncer S, Oray M, Yildirim Y, Camcioglu Y, Tugal-Tutkun I. Bilateral
intraocular calcification in necrotizing cytomegalovirus retinitis. Int
Ophthalmol. 2014.
84. Tzialla C, Decembrino L, Di Comite A, Bollani L, Colombo R, Stronati M
(2010) Colonic stricture and retinitis due to cytomegalovirus infection in an
immunocompetent infant. Pediatr Int 52(4):659–60
85. Sloan DJ, Taegtmeyer M, Pearce IA, Hart IJ, Miller AR, Beeching NJ (2008)
Cytomegalovirus retinitis in the absence of HIV or immunosuppression. Eur
J Ophthalmol 18(5):813–5
86. Welling JD, Tarabishy AB, Christoforidis JB (2012) Cytomegalovirus retinitis
after central retinal vein occlusion in a patient on systemic
immunosuppression: does venooclusive disease predispose to
cytomegalovirus retinitis in patients already at risk? Clin Ophthalmol 6:601–3.
doi:10.2147/OPTH.S28086
87. Takakura, et al. Viral Retinitis following Intraocular or Periocular
Corticosteroid Administration: A Case Series and Comprehensive Review of
the Literature. Ocular Immunology & Inflammation. 2014, 1–8.
88. Saidel M, Berreen J, Margolis T (2005) Cytomegalovirus Retinitis After
Intravitreous Triamcinolone in an Immunocompetent Patient. Am J
Ophthalmol 140(6):1141–1143
89. Delyfer M-N, Rougier M-B, Hubschman J-P, Aouizérate F, Korobelnik J-F
(2007) Cytomegalovirus retinitis following intravitreal injection of
triamcinolone: report of two cases. Acta ophthalmologica Scandinavica
85(6):681–3
90. Furukawa M. Cytomegalovirus Retinitis After IVTA treatment of a
Vitrecotmized Eye in an Immunocompetent Patient. Retinal Cases & Brief
Reports. 2007;1(4).
91. Hsu J (2007) Cytomegalovirus Retinitis After Treatment with Intravitreal
Triamcinolone Acetonide in an Immunocompetent Patient. Retinal Cases &
Brief Reports 1(4):208–210
92. Ufret-Vincenty RL, Singh RP, Kaiser PK (2007) Cytomegalovirus Retinitis after
Fluocinolone Acetonide (Retisert) Implant. Am J Ophthalmol 143:334–335
93. Park YS, Byeon SH (2008) Cytomegalovirus retinitis after intravitreous
triamcinolone injection in a patient with central retinal vein occlusion.
Korean J Ophthalmol 22(2):143–4
94. Sekiryu T, Iida T, Kaneko H, Saito M (2008) Cytomegalovirus retinitis after
intravitreal triamcinolone acetonide in an immunocompetent patient. Jpn J
Ophthalmol 52(5):414–6
95. Babiuch AS, Ravage ZB, Merrill PT (2010) Cytomegalovirus Acute Retinal
Necrosis in an Immunocompetent Patient After Sub-Tenon Triamcinolone
Injection. Retin Cases Brief Rep 4(4):364–365
Downes et al. Journal of Ophthalmic Inflammation and Infection  (2016) 6:3 Page 18 of 19
96. Shah AM, Oster SF, Freeman WR (2010) Viral retinitis after intravitreal
triamcinolone injection in patients with predisposing medical comorbidities.
Am J Ophthalmol 149(3):433–40
97. Toyokawa N, Kimura H, Kuroda S (2010) Cytomegalovirus Retinitis After
Subtenon TA and Intravitreal Injection of Anti-Vascular Endothelial Growth
Factor in an ImmunocompetentPatient with Age-Related Macular
Degeneration and Diabetes Mellitus. Jpn J Ophthalmol 54(2):166–8
98. Tugal-Tutkun I, Araz B, Cagatay A (2010) CMV retinitis after intravitreal
triamcinolone acetonide injection in a patient with Behçet’s uveitis.
International Ophthalmology 30(5):591–3
99. Vertes D, Snyers B, De Potter P (2010) Cytomegalovirus retinitis after low-
dose intravitreous triamcinolone acetonide in an immunocompetent
patient: a warning for the widespread use of intravitreous corticosteroids.
International Ophthalmology 30(5):595–7
100. Zaborowski AG. Cytomegalovirus Retinitis Following Intravitreal Triamcinolone
Acetonide in a Patient with Chronic Uveitis on Systemic Immunosuppression.
Ocular immunology and inflammation. 2013;(October):1–2
101. Jabs DA (1995) Ocular manifestations of HIV infection. Trans Am
Ophthalmol Soc 93:623–83
102. Jabs DA et al (2007) Longitudinal Study of the Ocular Complications of
AIDS 1. Ocular Diagnoses at Enrollment. Ophthalmology 114:4
103. Jabs DA et al (2007) Longitudinal Study of the Ocular Complications of
AIDS 2. Ocular Examination Results at Enrollment. Ophthalmology 114:4
104. Jabs DA (2011) Cytomegalovirus Retinitis and the Acquired
Immunodeficiency Syndrome—Bench to Bedside: LXVII Edward Jackson
Memorial Lecture. American journal of ophthalmology 151:2
105. Jabs DA et al (2010) Course of Cytomegalovirus Retinitis in the Era of Highly
Active Antiretroviral Therapy: Five-year Outcomes. Ophthalmology 117(11):
2152–2161
106. Urban, B. Et al. Immune Recovery Uveitis: Pathogenesis, Clinical Symptoms,
and Treatment. Mediators of Inflammation Volume 2014, Article ID 971417.
107. Ruiz Cruz, M, et al. Proposed Clinical Case Definition for Cytomegalovirus–
Immune Recovery Retinitis. HIV/AIDS CID 2014:59 (15 July)
108. Vishnevskia-Dai V, Shapira Y, Rahav G, Shimoni A, Somech R, Moisseiev J
(2015) Cytomegalovirus retinitis in HIV-negative patients: a practical
management approach. Ophthalmology 122(4):866–868
109. Miszewska-Szyszkowska D, Mikołajczyk N, Komuda-Leszek E, Wieczorek-
Godlewska R, Świder R, Dęborska-Materkowska D, Szmidt J, Durlik M (2015)
Severe cytomegalovirus infection in second kidney transplant recipient
treated with ganciclovir, leflunomide, and immunoglobulins, with
complications including seizures, acute HCV infection, drug-induced
pancytopenia, diabetes, cholangitis, and multi organ failure with fatal
outcome: a case report. Ann Transplant 20:169–74
110. Chan TS, Cheung CY, Yeung IY, Hwang YY, Gill H, Wong IY, Kwong YL
(2015) Cytomegalovirus retinitis complicating combination therapy with
rituximab and fludarabine. Ann Hematol 94(6):1043–7
111. Vannozzi L, Bacherini D, Sodi A, Beccastrini E, Emmi G, Giorni A (2015)
Menchini U. Cytomegalovirus retinitis following intravitreal dexamethasone
implant in a patient with central retinal vein occlusion, Acta Ophthalmol
112. Matsumoto A, Umeda K, Kawada K, Maeda S, Kinehara T, Saida S, Kato I,
Hiramatsu H, Watanabe K, Yasumi T, Heike T, Tsujikawa A, Uji A, Usami I, Ito
K, Adachi S (2015) Development of CMV retinitis in an antigenemia-negative
infant after cord blood transplantation. Rinsho Ketsueki 56(5):506–10
113. Jeon S, Lee WK (2015) Cytomegalovirus Retinitis in a Human
Immunodeficiency Virus-negative Cohort: Long-term Management and
Complications. Ocul Immunol Inflamm 11:1–8
114. Cunningham ET Jr, Downes KM, Chee S-P, Zierhut M. Cytomegalovirus
retinitis and uveitis. Ocul Immunol Inflamm. 2015, In press.
115. Cunningham ET Jr, Hubbard LD, Danis RP, Holland GN (2011) Proportionate
topographic areas of retinal zones 1, 2, and 3 for use in describing
infectious retinitis. Arch Ophthalmol 129(11):1507–8
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Downes et al. Journal of Ophthalmic Inflammation and Infection  (2016) 6:3 Page 19 of 19
